3 de noviembre de 2016 / 17:42 / hace 10 meses

BRIEF-PMPRB reaches agreement with Baxalta Canada on reporting requirements for leukemia drug

Nov 3 (Reuters) - Patented Medicine Prices Review Board:

* Canada's drug price watchdog reaches agreement with drug-maker on reporting requirements for leukemia drug

* Hearing panel issued order on Oct 28, requiring Baxalta Canada to provide PMPRB with requirements for leukemia drug

* Issued order to Baxalta to provide PMPRB with pricing,sales info required by section 80 of Patent Act,sections 3 and 4 of Patented Medicines Regulations

* Order relates to medicine Oncaspar, which is used in treatment of patients with acute lymphoblastic leukemia

* Baxalta agreed to provide information sought by PMPRB for period commencing July 1, 2015, when Baxalta began selling Oncaspar in Canada

* Hearing panel's order resolved matter with Baxalta and, as such, no hearing will be held in November 2016 Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below